Menu ×


Bivalirudin and Desmopressin Market Analysis by Application {Percutaneous Coronary Intervention (PCI) Procedures, Percutaneous Transluminal Coronary Angioplasty (PTCA) Procedures, and Others}; and by End User (Hospitals, Specialty Clinics, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2022-2031

  • Report ID: 266
  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • A definitive agreement has been signed between Pfizer Inc. and Global Blood Therapeutics, Inc. Pfizer Inc. will acquire GBT, a biopharmaceutical company devoted to discovering and developing life-changing treatments for isolated patient groups.
  • AmbioPharm Inc., a leader in CDMO services for peptide APIs, announced the opening of its Shanghai campus and the appointment of members of its European executive team.

Global Bivalirudin and Desmopressin Market Size, Forecast, and Trend Highlights Over 2022 - 2031


The global bivalirudin and desmopressin market is estimated to garner significant revenue by the end of 2031 by growing at a CAGR of ~5% over the forecast period, i.e., 2022 – 2031. Further, the market generated modest revenue in the year 2021. Increasing demand for bivalirudin is being driven by its application in the treatment of cancer and cardiovascular disease. In addition, rising incidences of cardiovascular diseases worldwide are expected to drive market growth during the forecast period. According to the World Health Organization, Cardiovascular disease is one of the leading causes of death worldwide. CVDs caused an estimated 17.9 million deaths in 2019, which accounted for 32% of all deaths worldwide. Furthermore, increasing demand for desmopressin owing to its use for nocturia and bedtime wetting is expected to drive global bivalirudin and desmopressin market growth. Desmopressin medicines have also been extensively used in conditions such as diabetes insipidus, which causes the body to produce excessive amounts of urine.


Get more information on this report: Request Sample PDF

Bivalirudin is a synthetic residue compound that inhibits direct thrombin. Especially in people with severe chest pain or those undergoing angioplasty, it prevents the formation of blood clots. Also, heart attack patients who undergo percutaneous coronary intervention are treated with this drug. Likewise, desmopressin is an artificial replacement for vasopressin and acts by limiting the amount of water that is excreted in the urine. Moreover, awareness programs and initiatives regarding bedwetting and enuresis medical conditions are market trends expected to propel the demand for desmopressin during the forecast period. For instance, in September 2021, an organization launched a public awareness campaign to raise awareness about the problem of enuresis in children. In 2015, World Bedwetting Day was initiated to promote awareness of enuresis as a treatable medical condition.

Global Bivalirudin and Desmopressin Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Percutaneous Coronary Interventions (PCI) Procedures Among Heart Patients - According to the American Heart Association, the number of percutaneous coronary interventions (PCI) in the United States reaches more than 600 000 each year, resulting in over USD 12 billion in healthcare expenditures. Percutaneous coronary intervention is a non-surgical procedure that involves placing a small stent into narrowed blood vessels in the heart caused by atherosclerosis using a thin flexible tube. Percutaneous Coronary Intervention (PCI) is becoming increasingly popular to treat acute coronary syndrome. With the use of anticoagulation therapy increasing during PCI, the risk of thrombotic complications is being reduced. This factor is expected to enlarge global bivalirudin and desmopressin market size during the forecast period. 
  • Growing Patients of Cancer Worldwide – According to the World Health Organization, cancer is the leading cause of death worldwide. In 2020, nearly 10 million people died from this disease. There are about 400 000 cases of cancer in children each year.
  • Increasing Number Of Elderly People Suffering From Nocturia- In a study it was found that about 65% of men and 73% of women over 40 admitted getting up to use the bathroom at least once per night. It is estimated that approximately 50% of men who are 70 years old wake up at least twice a night to relieve themselves. The number of elderly people who suffer from nocturia may reach up to 80%.
  • Higher Prevalence Of Coronary Artery Disease Worldwide - According to the Centers for disease control and prevention in 2020, 382,820 people died from coronary heart disease. The incidence of CAD among adults aged 20 and over is about 7.2%. The proportion of deaths from CAD among adults younger than 65 years old is about 2 in 10.
  • Globally Rising Patients Of Diabetes - According to International Diabetes Federation, Diabetes affected approximately 537 million adults (20-79 years) in 2021. Diabetes is expected to affect 643 million people by 2030 and 783 million by 2045. A common sign and symptom of diabetes is excessive thirst and urination. People who suffer from diabetes urinate four to seven times a day on average. Thus, rising cases of diabetes worldwide are estimated to propel the demand for desmopressin during the forecast period. 


  • High Cost Associated With the Bivalirudin Drug 
  • Health Concerns Such As Bleeding, Difficulty Breathing, and Sudden Numbness
  • Unawareness Among People Regarding Less Medical Treatments

The global bivalirudin and desmopressin market is segmented and analyzed for demand and supply by application into percutaneous coronary intervention (PCI) procedures, percutaneous transluminal coronary angioplasty (PTCA) procedures, and others. Among these, the percutaneous coronary intervention (PCI) procedure segment is anticipated to capture the largest market size in the global bivalirudin and desmopressin market owing to the rising incidences of adverse cardiovascular (CVDs) and heart diseases among population. For instance, cardiovascular disease (CVD) was the leading cause of death in the United States in 2018, followed by stroke (17%), high blood pressure (11%), heart failure (9.5%), arteries diseases (3%), and other CVD (17.2%). PCI procedures are intended to reduce adverse cardiovascular diseases. PCI is further enhanced by antithrombotic and antiplatelet therapies as an adjunct to reduce MACE rates. This factor is expected to fuel the segment growth during the forecast period.  

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Bivalirudin and Desmopressin Market Regional Synopsis

Regionally, the global bivalirudin and desmopressin market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2031. Coronary artery disease (CAD) prevalence among the population resulted in increasing percutaneous coronary intervention (PCI) procedures in the region. It was observed that nearly 960,000 percutaneous coronary intervention procedures are performed each year in the United States. Percutaneous coronary intervention (PCI) also known as angioplasty, is a procedure to open a blocked or narrowing artery. Moreover, increasing cases of cardiovascular diseases and heart diseases in the region are expected to drive market growth during the forecast period. For instance, there were approximately 695,000 deaths caused by heart disease in the United States in 2020.


The global bivalirudin and desmopressin market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global bivalirudin and desmopressin market includes the following segments:

By Application

  • Percutaneous Coronary Intervention (PCI) Procedures
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Procedures
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

Top Featured Companies Dominating the Global Bivalirudin and Desmopressin Market

  • Pfizer, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Hainan Shuangcheng Pharmaceuticals Co. Ltd.
  • AmbioPharm Inc.
  • Abott India Limited (India)
  • The Medicines Company
  • Sun Pharmaceuticals Industries Limited
  • Ferring Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Chengdu Shengnuo Biopharm Co. Ltd.
  • ScinoPharm Taiwan Ltd



Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved